Titre :

Long-term Outcomes of Thalidomide Therapy for Adults With Refractory Crohn's Disease.

Auteur(s) :

Simon, Marion [Auteur]
Quantitative methods for stochastic models in physics [MEPHYSTO]
Pariente, Benjamin [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Lambert, Jérôme [Auteur]
Bureau de Recherches Géologiques et Minières [BRGM]
Cosnes, Jacques [Auteur]
CHU Saint-Antoine [AP-HP]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Bouhnik, Yoram [Auteur]
Service de Gastroentérologie [Hôpital Beaujon]
Marteau, Philippe [Auteur]
Service de Chirurgie d'Oncologie Digestive [CHU Lariboisière]
Allez, Matthieu [Auteur]
Hôpital Saint-Louis
Colombel, Jean-Frédéric [Auteur]
Department of Medicine [New York]
Gornet, Jean-Marc [Auteur]
Hôpital Saint-Louis

Titre de la revue :

Clinical Gastroenterology and Hepatology

Pagination :

966–972.e2

Éditeur :

WB Saunders

Date de publication :

2015-11-18

ISSN :

1542-3565

Discipline(s) HAL :

Chimie/Chimie organique

Résumé en anglais : [en]

Little is known about the efficacy and safety of thalidomide therapy for patients with refractory Crohn's disease (CD), particularly in respect to long-term outcomes of patients. We conducted a retrospective multicenter ...
Lire la suite >Little is known about the efficacy and safety of thalidomide therapy for patients with refractory Crohn's disease (CD), particularly in respect to long-term outcomes of patients. We conducted a retrospective multicenter observational study to evaluate thalidomide efficacy and the probability of its withdrawal because of either toxicity or lack/loss of efficacy. We analyzed data from 77 patients with active intestinal and/or perineal CD, refractory to conventional immunosuppressive therapies, treated with thalidomide at 5 tertiary referral inflammatory bowel disease centers in France. We also analyzed the long-term efficacy of thalidomide. Fifty-four percent of the patients were in clinical remission after thalidomide treatment within the first year. The proportions of patients from whom thalidomide was withdrawn because of lack/loss of efficacy and/or toxicity were 35% at 3 months of treatment, 69% at 12 months, and 88% at 24 months. The proportions of patients from whom thalidomide was withdrawn because of toxicity alone were 22% at 3 months, 34% at 12 months, and 46% at 24 months. Overall, neuropathy occurred in 30 patients and was the main reason for thalidomide withdrawal. On the basis of a retrospective multicenter observational study, thalidomide therapy is effective in most patients with refractory active intestinal and/or perineal CD. However, its toxicity limits its use as a maintenance therapy.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Collections :

• Laboratoire Paul Painlevé - UMR 8524

Source :

Harvested from HAL